1. Home
  2. CHWY vs BIIB Comparison

CHWY vs BIIB Comparison

Compare CHWY & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chewy Inc.

CHWY

Chewy Inc.

HOLD

Current Price

$33.48

Market Cap

14.2B

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$181.52

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHWY
BIIB
Founded
2010
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.2B
24.2B
IPO Year
2019
1991

Fundamental Metrics

Financial Performance
Metric
CHWY
BIIB
Price
$33.48
$181.52
Analyst Decision
Strong Buy
Buy
Analyst Count
23
23
Target Price
$45.29
$176.48
AVG Volume (30 Days)
6.2M
1.9M
Earning Date
12-10-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.35
10.97
Revenue
$12,345,235,000.00
$10,065,900,000.00
Revenue This Year
$8.37
$3.61
Revenue Next Year
$7.82
N/A
P/E Ratio
$95.82
$16.52
Revenue Growth
9.17
4.77
52 Week Low
$29.83
$110.04
52 Week High
$48.62
$185.17

Technical Indicators

Market Signals
Indicator
CHWY
BIIB
Relative Strength Index (RSI) 44.82 72.92
Support Level $32.96 $174.53
Resistance Level $35.09 $182.94
Average True Range (ATR) 1.17 5.22
MACD 0.10 0.25
Stochastic Oscillator 59.11 83.54

Price Performance

Historical Comparison
CHWY
BIIB

About CHWY Chewy Inc.

Chewy is the largest e-commerce petcare retailer in the US, generating $11.9 billion in fiscal 2024 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a stand-alone company in 2019 after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods like crates, leashes, and bowls.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: